QUIXIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Quixin, and when can generic versions of Quixin launch?
Quixin is a drug marketed by Santen and is included in one NDA.
The generic ingredient in QUIXIN is levofloxacin. There are thirty-one drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the levofloxacin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Quixin
A generic version of QUIXIN was approved as levofloxacin by RISING on December 20th, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for QUIXIN?
- What are the global sales for QUIXIN?
- What is Average Wholesale Price for QUIXIN?
Summary for QUIXIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 98 |
Clinical Trials: | 2 |
Patent Applications: | 5,337 |
DailyMed Link: | QUIXIN at DailyMed |
Recent Clinical Trials for QUIXIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Roswell Park Cancer Institute | Phase 4 |
National Cancer Institute (NCI) | Phase 4 |
Children's Oncology Group | Phase 3 |
US Patents and Regulatory Information for QUIXIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Santen | QUIXIN | levofloxacin | SOLUTION/DROPS;OPHTHALMIC | 021199-001 | Aug 18, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for QUIXIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Santen | QUIXIN | levofloxacin | SOLUTION/DROPS;OPHTHALMIC | 021199-001 | Aug 18, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Santen | QUIXIN | levofloxacin | SOLUTION/DROPS;OPHTHALMIC | 021199-001 | Aug 18, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Santen | QUIXIN | levofloxacin | SOLUTION/DROPS;OPHTHALMIC | 021199-001 | Aug 18, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Santen | QUIXIN | levofloxacin | SOLUTION/DROPS;OPHTHALMIC | 021199-001 | Aug 18, 2000 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for QUIXIN
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Chiesi Farmaceutici S.p.A | Quinsair | levofloxacin | EMEA/H/C/002789 Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.Consideration should be given to official guidance on the appropriate use of antibacterial agents. |
Authorised | no | no | no | 2015-03-25 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for QUIXIN
See the table below for patents covering QUIXIN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 8801251 | ⤷ Sign Up | |
Canada | 1241599 | UTILISATION EN OPHTALMOLOGIE DE LA NORFLOXACINE ET DES ANTIBIOTIQUES APPARENTES (OPHTHALMIC USE OF NORFLOXACIN AND RELATED ANTIBIOTICS) | ⤷ Sign Up |
Japan | H04364185 | PYRIDOBENZOXAZINE DERIVATIVE | ⤷ Sign Up |
Australia | 567979 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for QUIXIN
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0206283 | C980016 | Netherlands | ⤷ Sign Up | PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606 |
0206283 | 98C0041 | Belgium | ⤷ Sign Up | PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606 |
0206283 | SPC/GB97/085 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |